Synonym
K145; K-145; K 145; K145 HCl; K145 hydrochloride.
IUPAC/Chemical Name
(Z)-3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)thiazolidine-2,4-dione hydrochloride
InChi Key
HADFDMGQKBGVAV-NKBLJONXSA-N
InChi Code
InChI=1S/C18H24N2O3S.ClH/c1-2-3-13-23-15-9-7-14(8-10-15)5-4-6-16-17(21)20(12-11-19)18(22)24-16;/h6-10H,2-5,11-13,19H2,1H3;1H/b16-6-;
SMILES Code
O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2.[H]Cl
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, and in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO or water.
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#:
CAS#1449240-68-9 (K145 HCl salt);
CAS#1309444-75-4 (K145 free base)
Biological target:
K145 hydrochloride is a SphK2 inhibitor with an IC50 of 4.3 µM.
In vitro activity:
The anti-proliferative and apoptotic effects of K145 in U937 cells were evaluated. As shown in Figure 6A, K 145 significantly inhibited the growth of U937 cells cultured in the presence of 10% serum in a concentration-dependent manner. K145 also significantly induced apoptosis in U937 cells under these experimental conditions (Figure 6B). Notably, K145 induced mainly late apoptosis with a very small percentage of necrotic cells after 24 h treatment in the presence of 10% serum.
Reference: PLoS One. 2013;8(2):e56471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577900/
In vivo activity:
The anticancer activity of K145 to inhibit the tumor growth of U937 cells was examined in nude mice (BALB/c-nu) by oral administration. As shown in Figure 10A, tumor weights of K145-treated mice were significantly less than that in vehicle-treated mice and K145 exhibited antitumor activity (TGI for K145 was 51.25%). Visual examination of the tumor samples also confirmed the significant inhibition of U937 tumor growth by K145 (Figure 10B-C). Collectively, the results of in vivo studies with K145 by oral administration demonstrated that K145 is orally available to inhibit the growth of U937 tumors at 50 mg/kg dose.
Reference: PLoS One. 2013;8(2):e56471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577900/
|
Solvent |
mg/mL |
mM |
| Solubility |
| Water |
126.7 |
363.60 |
| DMSO |
30.0 |
86.09 |
| DMSO:PBS (pH 7.2) (1:1) |
0.5 |
1.43 |
| DMF |
10.0 |
28.70 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
348.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865.
2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.
In vitro protocol:
1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865.
2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.
In vivo protocol:
1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865.
2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.
1: Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PubMed PMID: 23437140; PubMed Central PMCID: PMC3577900.
1. Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SM. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia. 2022 Jan;24(1):1-11. doi: 10.1016/j.neo.2021.11.009. Epub 2021 Nov 23. PMID: 34826777; PMCID: PMC8626806.
2. Al-Shujairi WH, Clarke JN, Davies LT, Pitman MR, Calvert JK, Aloia AL, Pitson SM, Carr JM. In vitro and in vivo roles of sphingosine kinase 2 during dengue virus infection. J Gen Virol. 2019 Apr;100(4):629-641. doi: 10.1099/jgv.0.001245. Epub 2019 Mar 14. PMID: 30869582.
3. Wallington-Beddoe CT, Bennett MK, Vandyke K, Davies L, Zebol JR, Moretti PAB, Pitman MR, Hewett DR, Zannettino ACW, Pitson SM. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget. 2017 Jul 4;8(27):43602-43616. doi: 10.18632/oncotarget.17115. PMID: 28467788; PMCID: PMC5546428.
